| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8656976 | Atherosclerosis | 2018 | 6 Pages |
Abstract
The observed lipid reductions and side effects profile of PCSK9 inhibitors in a routine care setting were comparable to observations in clinical trials.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Robert M. Stoekenbroek, Merel L. Hartgers, Roger Rutte, Douwe D. de Wijer, Erik S.G. Stroes, G. Kees Hovingh,